Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
1 clinical trials · Condition
◉ Watch Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
| Record | Firm | Date |
|---|---|---|
| The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients. (NCT05931328) | The First Affiliated Hospital with Nanjing Medical University | 2022-10-15 |
Track Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.